SETDB1 binding to SMAD3 methylates and suppresses T cell receptor-induced IL-2 transcription, presenting an additional mechanism of SETDB1 involvement in ovarian cancer tumorigenesis [75,106]. This evidence concerns the gene SETDB1 and ovarian carcinoma.